Luspatercept | All | Licensing, EU CTD Dossiers, Formulation Suppliers | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Luspatercept
FDF Dossiers

European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

Contact Supplier

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

pharmacompass-2-m-2025-10-20

Luspatercept

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 2 NDC API

2 API Suppliers
2 NDC API

DEVELOPMENTS

41 Drugs in Development

41 Drugs in Development

FINISHED DOSAGE FORMULATIONS

8 FDF Dossiers, 2 FDA Orange Book, 4 Europe, 2 Canada

8 FDF Dossiers
2 FDA Orange Book
4 Europe
2 Canada

DIGITAL CONTENT

59 News #PharmaBuzz

59 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 8 Annual Reports

1 US Medicaid Prescriptions
8 Annual Reports

MARKET PLACE

1 FDF Dossiers

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

8 Health Canada Patents

8 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

8 All

01 6Bristol Myers Squibb

02 2Celgene Corporation

filter Dosage Reset all filters

8 All

01 2POWDER FOR SOLUTION

02 2POWDER;SUBCUTANEOUS

03 2Powder For Injectable Solution

04 2Powder For Solution For Injection

filter Regulatory Info Reset all filters

8 All

01 2Approved

02 2Authorized

03 2Schedule D

04 2Blank

filter Brand Name Reset all filters

8 All

01 4REBLOZYL

02 4Reblozyl

filter Country Reset all filters

8 All

01 2Canada

02 2Spain

03 2Sweden

04 2USA

List of Suppliers

Product Main Page

01

Bristol Myers Squibb

ACI Convention

Not Confirmed

Bristol Myers Squibb

ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info : Approved

Registration Country : Sweden

Luspatercept

Brand Name : Reblozyl

Dosage Form : Powder For Solution For Injection

Dosage Strength : 25mg

Packaging :

Approval Date : 25/06/2020

Application Number : 20190430000030

Regulatory Info : Approved

Registration Country : Sweden

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Bristol Myers Squibb

ACI Convention

Not Confirmed

Bristol Myers Squibb

ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info : Approved

Registration Country : Sweden

Luspatercept

Brand Name : Reblozyl

Dosage Form : Powder For Solution For Injection

Dosage Strength : 75mg

Packaging :

Approval Date : 25/06/2020

Application Number : 20190430000047

Regulatory Info : Approved

Registration Country : Sweden

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Bristol Myers Squibb

ACI Convention

Not Confirmed

Bristol Myers Squibb

ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info : Schedule D

Registration Country : Canada

LUSPATERCEPT

Brand Name : REBLOZYL

Dosage Form : POWDER FOR SOLUTION

Dosage Strength : 25MG/VIAL

Packaging :

Approval Date :

Application Number : 2505541

Regulatory Info : Schedule D

Registration Country : Canada

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Bristol Myers Squibb

ACI Convention

Not Confirmed

Bristol Myers Squibb

ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info : Schedule D

Registration Country : Canada

LUSPATERCEPT

Brand Name : REBLOZYL

Dosage Form : POWDER FOR SOLUTION

Dosage Strength : 75MG/VIAL

Packaging :

Approval Date :

Application Number : 2505568

Regulatory Info : Schedule D

Registration Country : Canada

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Bristol Myers Squibb

ACI Convention

Not Confirmed

Bristol Myers Squibb

ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info : Authorized

Registration Country : Spain

Luspatercept

Brand Name : Reblozyl

Dosage Form : Powder For Injectable Solution

Dosage Strength : 75MG

Packaging :

Approval Date : 2020-08-18

Application Number : 1201452002

Regulatory Info : Authorized

Registration Country : Spain

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Bristol Myers Squibb

ACI Convention

Not Confirmed

Bristol Myers Squibb

ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info : Authorized

Registration Country : Spain

Luspatercept

Brand Name : Reblozyl

Dosage Form : Powder For Injectable Solution

Dosage Strength : 25MG

Packaging :

Approval Date : 2020-08-18

Application Number : 1201452001

Regulatory Info : Authorized

Registration Country : Spain

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Celgene Corporation

ACI Convention

Not Confirmed

Celgene Corporation

ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info :

Registration Country : USA

LUSPATERCEPT-AAMT

Brand Name : REBLOZYL

Dosage Form : POWDER;SUBCUTANEOUS

Dosage Strength : 25MG/VIAL

Packaging :

Approval Date :

Application Number : 761136

Regulatory Info :

Registration Country : USA

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

Celgene Corporation

ACI Convention

Not Confirmed

Celgene Corporation

ACI Convention

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info :

Registration Country : USA

LUSPATERCEPT-AAMT

Brand Name : REBLOZYL

Dosage Form : POWDER;SUBCUTANEOUS

Dosage Strength : 75MG/VIAL

Packaging :

Approval Date :

Application Number : 761136

Regulatory Info :

Registration Country : USA

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!